Project: Identifying patients at risk of relapse of (metastatic) colorectal cancer with targeted imaging

META-DETECT will develop a multi-target imaging agent to diagnose, stage and determine the risk of relapse in colorectal cancer (CRC). The novel imaging agent will combine llama VHH antibody fragments with a nanoparticle that can be visualized with numerous imaging instruments rendering an unparalleled sensitivity and specificity. It will be able to accurately localize and characterize tumours, and predict the risk for CRC relapse, which will significantly improve the chance of survival.

Acronym META-DETECT (Reference Number: 10610)
Duration 01/09/2016 - 01/09/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
24657 QVQ Holding B.V. Coordinator Netherlands
24658 Surflay Nanotec GmbH Partner Germany
24659 Pipeline Biotech A/S Partner Denmark
24660 Karolinska Institutet Partner Sweden